Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q4 2016 value amounting to $2.9 million.

  • Lineage Cell Therapeutics' Treasury Shares fell 8396.83% to $2.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was $2.9 million, marking a year-over-year decrease of 8396.83%. This contributed to the annual value of $2.9 million for FY2016, which is 8396.83% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Treasury Shares stood at $334000.0, which was down 3333.33% from $334000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Treasury Shares peaked at $939000.0 during Q4 2022, and registered a low of $334000.0 during Q1 2025.
  • In the last 4 years, Lineage Cell Therapeutics' Treasury Shares had a median value of $501000.0 in 2024 and averaged $537200.0.
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 41381.39% in 2013, then crashed by 8546.51% in 2016.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Treasury Shares stood at $8.4 million in 2012, then surged by 413.81% to $43.0 million in 2013, then plummeted by 53.78% to $19.9 million in 2014, then fell by 9.34% to $18.0 million in 2015, then tumbled by 83.97% to $2.9 million in 2016.
  • Its Treasury Shares stands at $2.9 million for Q4 2016, versus $2.9 million for Q3 2016 and $2.9 million for Q2 2016.